Tissue Regenix May Attract Suitors After Covidien Deal

Tissue Regenix Group Plc, a British maker of products to repair skin and other tissues, would be an attractive acquisition target, given its tax and structural advantages, Chief Executive Officer Antony Odell said.

Deal activity will persist, especially in the wound-care sector of the medical-device industry, following Medtronic Inc.’s $42.9 billion purchase of Covidien Plc, Odell said today in a phone interview. Tissue Regenix, which has a market value of 181 million pounds ($307 million), is split into three operating units, orthopedic, wound care and cardiac products, making it easier to sell them individually, he said.